TANG CAPITAL PARTNERS LP
CIK 1191935 · last filed 2024-09-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LJPC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 210
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Singular Genomics Systems, Inc. (OMIC) Delisted | 10%+ Owner | 340,000 | $20.01 | $6.80M | $5.42M | 1 | 2024-09-18 |
| RAIN | 10%+ Owner | 3,850,513 | $0.57 | $2.21M | $3.69M | 3 | 2023-12-18 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 4,299,852 | $1.48 | $6.36M | $491.3K | 1 | 2023-05-10 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | 10%+ Owner | 5,279,801 | $1.88 | $9.93M | $257.9K | 1 | 2023-03-14 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | 10%+ Owner | 9,849,224 | $6.22 | $61.26M | $129.62M | 11 | 2021-12-01 |
| APVO | 10%+ Owner | 1 | $1.52 | $2 | $23.94M | 3 | 2021-11-26 |
| Odonate Therapeutics, Inc. (ODT) Delisted | 10%+ Owner | 15,238,782 | $1.12 | $17.07M | $16.61M | 5 | 2020-09-30 |
| HRTX | 10%+ Owner | 8,532,156 | $0.31 | $2.67M | $33.28M | 3 | 2018-04-02 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 1,238,543 | $58.70 | $72.70M | $1.19M | 2 | 2013-10-28 |
| HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted | Director | 528,767 | — | — | $2.50M | 3 | 2010-05-26 |
| VNDA | 10%+ Owner | 2,715,852 | $4.00 | $10.85M | -$3.42M | 7 | 2010-01-19 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 6,040,136 | — | — | $12.95M | 7 | 2009-03-10 |
| NEOSE TECHNOLOGIES INC (NTEC) Delisted | 10%+ Owner | 0 | $9.63 | $0 | $520.7K | 8 | 2008-11-12 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 13,500 | — | — | $51.2K | 3 | 2008-10-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | 10%+ Owner | 211,383 | — | — | $5.22M | 3 | 2008-05-16 |
Recent Filings · Page 4 of 8
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-10-28 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +171,429 | $3.00M | EDGAR |
| 2013-09-23 | Mirati Therapeutics, Inc. (MRTX) Delisted | Sell (S) | −110,694 | -$1.81M | EDGAR |
| 2012-07-27 | — | Grant (A) | +28,571,430 | $15.00M | |
| 2012-05-09 | — | Exer (X) | — | $0 | |
| 2011-04-26 | — | Grant (A) | — | $0 | |
| 2010-05-26 | HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted | Grant (A) | +287,673 | $0 | EDGAR |
| 2010-01-19 | VNDA | Sell (S) | −164,700 | -$1.77M | EDGAR |
| 2010-01-06 | VNDA | Sell (S) | −436,500 | -$5.06M | EDGAR |
| 2009-07-21 | VNDA | Sell (S) | — | $0 | EDGAR |
| 2009-05-28 | VNDA | Sell (S) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.